Anti-BTN1A1 (ICT-01-N297A) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD.

Anti-BTN1A1 (ICT-01-N297A) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD.

Anti-BTN1A1 (ICT-01-N297A) is a humanized monoclonal antibody targeting BTN1A1. It can be used in treatment of advanced solid tumors. MW :146.2 KD.

Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson’s disease. MW: 146.74 KD.

Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson’s disease. MW: 146.74 KD.

Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson’s disease. MW: 146.74 KD.

Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD.

Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD.

Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD.

Anti-CAPRIN1 is a humanized antibody targeting CAPRIN-1. It is used as a novel and universal target for cancer therapies. MW :141.44 KD.

Anti-CAPRIN1 is a humanized antibody targeting CAPRIN-1. It is used as a novel and universal target for cancer therapies. MW :141.44 KD.

Anti-CAPRIN1 is a humanized antibody targeting CAPRIN-1. It is used as a novel and universal target for cancer therapies. MW :141.44 KD.

Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD.

Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD.

Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD.

Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD.

Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD.

Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD.

Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD.

Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD.

Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD.

Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD.

Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD.

Anti-CCR7 / CD197 (R707) is a fully human antibody targeting CCR7 signaling and function. It exhibits the potential to prevent acute graft-versus-host disease (aGVHD).MW :145.36 KD.

Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.

Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.

Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD.

Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD.

Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD.

Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD.

Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD.

Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD.

Anti-CD19 (Immunomedics hA19) is a humanized IgG1kappa monoclonal antibody targated against CD19 with the potential to treat autoimmune diseases. MW: 147.32 KD.

Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD.

Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD.

Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD.

Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD.

Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD.

Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD.

Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD.

Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD.

Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD.

Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD.

Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD.

Anti-CD4 (TRX1) is a non-depleting monoclonal IgG1 antibody against CD4. MW : 145.98 KD.